Related Experiment Video

Updated: Jun 27, 2026

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
11:27

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

Inhibitory kappa B kinase-beta is a target for specific nuclear factor kappa B-mediated delayed cardioprotection

Nancy C Moss1, Ru-Hang Tang, Monte Willis

  • 1Department of Surgery, University of North Carolina, Chapel Hill, North Carolina 27599, USA.

The Journal of Thoracic and Cardiovascular Surgery
|November 26, 2008
PubMed
Abstract

Insights

Targeting inhibitory kappa B kinase-beta during reperfusion protects the heart from injury. This approach, unlike proteasome inhibition, offers delayed cardioprotection by suppressing nuclear factor-kappaB signaling, presenting a clinically relevant option.

Area of Science:

  • Cardiovascular Research
  • Molecular Cardiology
  • Ischemia-Reperfusion Injury

Background:

  • Myocardial ischemia/reperfusion (I/R) injury is a significant clinical challenge.
  • Current protective strategies often require pre-ischemic intervention, limiting their use.
  • The nuclear factor-kappaB (NF-κB) pathway is implicated in I/R injury.

Purpose of the Study:

  • To investigate the cardioprotective effects of targeting inhibitory kappa B kinase-beta (IKK-β) and the 26S cardiac proteasome during reperfusion.
  • To determine if these targets offer protection when administered after the ischemic insult.
  • To elucidate the specific molecular mechanisms underlying any observed cardioprotection.

Main Methods:

  • Mice underwent 30 minutes of left anterior descending artery occlusion followed by reperfusion.
  • Inhibitors of IKK-β (Compound A) or proteasome (PS-519), or vehicle, were administered at reperfusion or 2 hours later.
  • Infarct size, ejection fraction, and protein expression (p-p65, IL-6, TNF-α) were assessed.

Main Results:

  • Both IKK-β and proteasome inhibition significantly reduced infarct size and preserved ejection fraction.
  • IKK-β inhibition provided delayed cardioprotection, reducing infarct size even when administered 2 hours post-reperfusion.
  • IKK-β inhibition specifically suppressed phosphorylated-p65, IL-6, and TNF-α, while proteasome inhibition did not.

Conclusions:

  • IKK-β and proteasome inhibition at reperfusion attenuate I/R injury.
  • Only IKK-β inhibition confers cardioprotection via specific suppression of NF-κB signaling.
  • Targeted IKK-β inhibition offers a clinically relevant, delayed therapeutic option for myocardial I/R injury.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...